The World Health Organization on Wednesday said a clinical trial in 52 countries will study three anti-inflammatory drugs as potential treatments for COVID-19 patients.
“These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients,” it said in a statement.
Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn’s Disease and rheumatoid arthritis.
New therapies selected with potential to reduce COVID-19 death risk: WHO
4 years ago
